EP Patent

EP4223310A3 — Recombinant human acid alpha-glucosidase

Assigned to Amicus Therapeutics Inc · Expires 2023-10-11 · 3y expired

What this patent protects

Provided are a recombinant acid α-glucosidase and pharmaceutical composition comprising a recombinant acid α- glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one…

USPTO Abstract

Provided are a recombinant acid α-glucosidase and pharmaceutical composition comprising a recombinant acid α- glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa. Also provided herein are methods of producing, purifying, and formulating the recombinant acid α-glucosidase or pharmaceutical composition for administration to a subject and methods of treating a disease or disorder such as Pompe disease using the recombinant acid α-glucosidase or pharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number
EP4223310A3
Jurisdiction
EP
Classification
—
Expires
2023-10-11
Drug substance claim
No
Drug product claim
No
Assignee
Amicus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.